UQ1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
AMT-130 Regulatory ProgressSubmitting AMT-130 applications in both the U.S. and U.K. marks a major transition from clinical development toward potential commercialization. The therapy’s Breakthrough, RMAT and Fast Track designations may support regulatory interaction and strengthen uniQure’s position in central nervous system gene therapy.
Long-term AMT-130 Efficacy SignalDurable follow-up showing continued disease-progression slowing is strategically important because it supports AMT-130’s potential disease-modifying profile beyond an early clinical signal. If regulators accept the evidence, the data could underpin approval, commercial differentiation and broader platform credibility.
Extended Financial RunwayA cash position sufficient to fund operations into 2030 gives uniQure time to pursue confirmatory development and prepare for potential commercialization without immediate financing pressure. This strengthens strategic flexibility and reduces the risk that near-term capital needs disrupt clinical or regulatory execution.
Bears Say
Persistent Cash Burn And Deep LossesThe company remains far from self-funded operations, with substantial operating and free-cash-flow losses relative to its small revenue base. Continued investment in clinical programs and commercialization therefore depends on existing capital, future financing or collaboration proceeds, leaving execution sensitive to spending and timing.
AMT-191 Dose-limiting Liver ToxicityThe AMT-191 dosing pause interrupts development at the mid- and high-dose levels and requires an FDA-agreed monitoring and management plan. Although the events resolved with immunosuppression, additional safety work could delay dose optimization, increase development complexity and weaken the program’s near-term value.
AMT-130 Confirmatory-trial Execution BurdenAccelerated approval would not eliminate the need for rapid, substantial confirmatory execution. Aligning the randomized standard-of-care-controlled trial and advancing it toward enrollment around approval creates operational pressure, adds spending requirements and leaves continued commercial progress dependent on trial delivery.
uniQure News
UQ1 FAQ
What was uniQure N.V.’s price range in the past 12 months?
Currently, no data Available
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is CHF1.42B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -CHF1.005 earnings per share for the quarter, missing the consensus estimate of -CHF0.677 by -CHF0.328.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.75.
How many shares outstanding does uniQure N.V. have?
Currently, no data Available
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -CHF1.005 in its last earnings report, missing expectations of -CHF0.677. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in CH:UQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF42.74 (― Upside)
CHF42.74 (― Upside)
Blogger Sentiment
Neutral
CH:UQ1 Sentiment 59%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.40%
12-Months-Change
Fundamentals
Return on Equity
-111.96%
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
UQ1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.View all CH:UQ1 earnings summaries